Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
To date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and clinical characteristics of COVID-19 infection, the study investigators wish to compare the MRI aspects obtained in COVID-19 patients with and without anosmia, in the absence of other underlying neurological disorders.
Description: MRI; Voxels
Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; Voxels
Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; Voxels
Measure: Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; voxels, value between 0-1
Measure: Fractional anisotropy between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; voxels, value between 0-1
Measure: Fractional anisotropy between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; mm2/s
Measure: Mean diffusivity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; mm2/s
Measure: Mean diffusivity between COVID-19 patients with and without anosmia Time: Month 3Description: MRI; mm2/s
Measure: Radial diffusivity between COVID-19 patients with and without anosmia Time: Day 0Description: MRI; mm2/s
Measure: Radial diffusivity between COVID-19 patients with and without anosmia Time: Month 3Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Day 0Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Day 8Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Month 1Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today
Measure: Self-assessed olfactory and gustatory test Time: Month 2Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale (cut-offs: strang (>80), moderate (40-80), attenuated (<40)
Measure: Ability to detect odor Time: Day 0Description: Patient asked to describe whether a pinch of sugar on their tongue taste sweet or salty
Measure: Ability to taste a pinch of sugar Time: Day 0Description: MRI: absence/presence
Measure: Presence of thrombotic and hemorrhagic lesions Time: Day 0Description: MRI: absence/presence
Measure: Presence of thrombotic and hemorrhagic lesions Time: Month 3Description: Short Ti Inversion Recovery (STIR); presence/absence
Measure: Presence of lesions with hyperintensity Time: Day 0Description: Short Ti Inversion Recovery (STIR); presence/absence
Measure: Presence of lesions with hyperintensity Time: Month 3Description: beta voxels
Measure: Projection network analysis of all patients Time: Day 0Description: beta voxels
Measure: Projection network analysis of all patients Time: Month 3Description: beta voxels
Measure: Blinded independent component analysis of all patients Time: Day 0Description: beta voxels
Measure: Blinded independent component analysis of all patients Time: Month 3Description: beta voxels
Measure: default mode network analysis of all patients Time: Day 0Description: beta voxels
Measure: default mode network analysis of all patients Time: Month 3Description: beta voxels
Measure: executive control network analysis of all patients Time: Day 0Description: beta voxels
Measure: executive control network analysis of all patients Time: Month 3Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports